Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer.

about

Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer.

Item

http://www.wikidata.org/entity/Q48219547

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Tumor-infiltrating lymphocytes ...... ptor 2-positive breast cancer.

@en

Tumor-infiltrating lymphocytes ...... ptor 2-positive breast cancer.

@nl

type

Item

label

Tumor-infiltrating lymphocytes ...... ptor 2-positive breast cancer.

@en

Tumor-infiltrating lymphocytes ...... ptor 2-positive breast cancer.

@nl

prefLabel

Tumor-infiltrating lymphocytes ...... ptor 2-positive breast cancer.

@en

Tumor-infiltrating lymphocytes ...... ptor 2-positive breast cancer.

@nl

P1476

Tumor-infiltrating lymphocytes ...... eptor 2-positive breast cancer

@en

P2093

Futoshi Akiyama

http://www.w3.org/2001/XMLSchema#string

Hiroaki Inoue

http://www.w3.org/2001/XMLSchema#string

Shinji Ohno

http://www.w3.org/2001/XMLSchema#string

Takuji Iwase

http://www.w3.org/2001/XMLSchema#string

Yoshinori Ito

http://www.w3.org/2001/XMLSchema#string

P2860

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis.

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.

Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.

Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients

Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer

Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer

Targeting regulatory T cells.

P2888

s12282-017-0822-8

P304

268-274

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12282-017-0822-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rie Horii

P577

2017-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29185202

http://www.w3.org/2001/XMLSchema#string